Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention

Coronary Artery Disease

Volumn 23, Issue 8, 2012, Pages 523-527

  Bozbeyoglu, Emrah ^a   Satilmis, Seckin ^a   Aksu, Huseyin ^a   Yildirimturk, Ozlem ^a   Nurkalem, Zekeriya ^a  

^a Dr Siyami Ersek Thoracic and Cardiovascular Training and Research Hospital   (Turkey)

Author keywords

clopidogrel; no reflow; primary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN; TIROFIBAN;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; DRUG RESISTANCE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT RESPONSE;

CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DRUG RESISTANCE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RECOVERY OF FUNCTION; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84869505451     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283596c29     Document Type: Article

References (30)

1. Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 2003; 91:3H-11H.
2. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996; 27:494-503.
3. Wijns W, Kolh P, Danchin N, Mario CD, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology and the European Association for Cardiothoracic Surgery. Eur Heart J 2010; 31:2501-2555.
4. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients with persistent STsegment elevation. Eur Heart J 2008; 29:2909-2945.
5. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103:5-10.
6. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001; 358:527-533.
7. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema W, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154:221-231.
8. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
9. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913.
10. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787.
11. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93:456-458.
12. Angiolillo DJ, Ferná ndez-Ortiz A, Bernardo E, Barrera Ram?́rez C, Sabaté M, Fernandez C, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16:169-174.
13. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45:246-251.
14. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to VASP phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicentre randomized prospective study. J Am Coll Cardiol 2008; 51:1404-1411.
15. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015.
16. Schrö der R. Prognostic impact of early ST-segment resolution in acute ST elevation myocardial infarction. Circulation 2004; 110:506-510.
17. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006; 3:499-506.
18. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142-154.
19. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158.
20. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38:472-477.
21. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45:1157-1164.
22. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:171-175.
23. Park KW, Kang SH, Kang J, Jeon KH, Park JJ, Han JK, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. Heart 2012; 98:1000-1006.
24. Hobson AR, Qureshi Z, Banks P, Curzen N. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. Cardiovasc Ther 2009; 27:246-252.
25. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47:27-33.
26. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85:1699-1705.
27. Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, et al. Shifting the open artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 2001; 37:9-18.
28. De Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283-1294.
29. Van't Hof A, Liem A, de Boer M, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 1997; 350:615-619.
30. Schröder R, Dissmann R, Brüggemann T,Wegscheider K, Linderer T, Tebbe U, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24:384-391.